论文部分内容阅读
肢端肥大症病人生长激素(GH)分泌的动力学不正常,包括口服葡萄糖后GH不完全被抑制或反常性升高,给予左旋多巴或促甲状腺素释放激素(TRH)刺激后GH反而下降。目前有人从人胰腺肿瘤中鉴定并合成了生长激素释放因子(GRFs),它具有生长激素释放激素(GHRH)所必须具有的1～29有生物活性作用的氨基酸,而GRFs的作用也与GHRH相同。本文着重研究GRFs对GH的刺激试验是否可作为肢端肥大症的诊断依据。 29例肢端肥大症患者,年龄20～72岁。其中8例未经治疗,2例为经蝶手术者,5例经放射治疗,9例放疗加手术治疗,1例手术加服溴隐亭,1例单服
Acromegaly in patients with growth hormone (GH) secretion kinetics abnormalities, including GH after oral glucose is not completely inhibited or abnormal increase in levodopa or thyrotropin-releasing hormone (TRH) stimulated GH but decreased . At present, human growth hormone releasing factor (GRFs) have been identified and synthesized from human pancreatic tumors and have the 1-29 bioactive amino acids which are necessary for growth hormone releasing hormone (GHRH), and the effect of GRFs is also the same as that of GHRH . This article focuses on whether GRFs GH stimulation test can be used as a diagnosis of acromegaly. 29 cases of acromegaly patients, aged 20 to 72 years. Among them, 8 cases were untreated, 2 cases were transsphenoidal surgery, 5 cases were treated by radiotherapy, 9 cases were treated by radiotherapy and surgery, 1 case was treated with bromocriptine, 1 case